- Home
- RDWR vs GERN Comparison
RDWR vs GERN Comparison
Compare RDWR & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDWR
- GERN
- Stock Information
- Founded
- RDWR 1996
- GERN 1990
- Country
- RDWR Israel
- GERN United States
- Employees
- RDWR N/A
- GERN N/A
- Industry
- RDWR EDP Services
- GERN Biotechnology: Pharmaceutical Preparations
- Sector
- RDWR Technology
- GERN Health Care
- Exchange
- RDWR Nasdaq
- GERN Nasdaq
- Market Cap
- RDWR 1.0B
- GERN 853.5M
- IPO Year
- RDWR 1999
- GERN 1996
- Fundamental
- Price
- RDWR $29.22
- GERN $1.38
- Analyst Decision
- RDWR Hold
- GERN Buy
- Analyst Count
- RDWR 4
- GERN 7
- Target Price
- RDWR $27.00
- GERN $4.17
- AVG Volume (30 Days)
- RDWR 443.8K
- GERN 10.0M
- Earning Date
- RDWR 07-30-2025
- GERN 08-07-2025
- Dividend Yield
- RDWR N/A
- GERN N/A
- EPS Growth
- RDWR N/A
- GERN N/A
- EPS
- RDWR 0.27
- GERN N/A
- Revenue
- RDWR $281,874,000.00
- GERN $116,293,000.00
- Revenue This Year
- RDWR $10.38
- GERN $160.12
- Revenue Next Year
- RDWR $7.14
- GERN $55.01
- P/E Ratio
- RDWR $110.25
- GERN N/A
- Revenue Growth
- RDWR 9.54
- GERN 22264.04
- 52 Week Low
- RDWR $17.36
- GERN $1.17
- 52 Week High
- RDWR $29.70
- GERN $5.06
- Technical
- Relative Strength Index (RSI)
- RDWR 83.82
- GERN 42.89
- Support Level
- RDWR $28.07
- GERN $1.36
- Resistance Level
- RDWR $28.59
- GERN $1.57
- Average True Range (ATR)
- RDWR 0.94
- GERN 0.09
- MACD
- RDWR 0.23
- GERN -0.02
- Stochastic Oscillator
- RDWR 97.25
- GERN 7.69
About RDWR Radware Ltd.
Radware Ltd provides cyber security and application delivery solutions. The company provides solutions for cloud, on-premises, and software-defined data centers (SDDC). The solutions of the company secure the digital experience by providing infrastructure, application, and network protection and availability services to enterprises globally. The business segments of the company are Radware's Core Business and The Hawks' Business. The company derives maximum revenue from Radware's Core Business. It generates the majority of its revenue from the United States.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.